Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 11Prostatic Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vomiting 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Nodule 1Thyroid Neoplasms 1Thromboembolism 1Thrombocytopenia 1Stomatitis 1Spondylitis, Ankylosing 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Scleroderma, Localized 1Psoriasis 1Postoperative Hemorrhage 1Pleural Effusion 1Peritoneal Neoplasms 1Pancreatic Cyst 1Pain, Postoperative 1Pain 1

Interventions

Bevacizumab 112Fluorouracil 98Oxaliplatin 96Leucovorin 96Irinotecan 86Capecitabine 73Cetuximab 64Panitumumab 42pembrolizumab 38regorafenib 28Nivolumab 23IFL protocol 22Folfox protocol 21trifluridine tipiracil drug combination 14Radiotherapy 13durvalumab 11Gemcitabine 10Celecoxib 10tremelimumab 7binimetinib 7aflibercept 7Drug Therapy 7Disulfides 7Cyclophosphamide 7Trifluridine 6Trastuzumab 6Sunitinib 6Paclitaxel 6Immunoglobulin G 6Colonoscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Colorectal Neoplasms × Saline Solution × Clear all
NCT02134925 2026-05-28

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

National Cancer Institute (NCI)

Phase 2 Active not recruiting
110 enrolled 12 charts
Gastrointestinal

Colorectal Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
558 enrolled 17 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡